Maze Therapeutics to Participate in Three Upcoming Investor Conferences
Live webcasts and 60-day replays will be available in the Investors section of Maze’s website for its three September 2026 conference fireside chats.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Maze Therapeutics (MAZE) will participate in three September 2026 investor conferences, each featuring a management fireside chat.
The company appears at the Wells Fargo 21st Annual Healthcare Conference on September 9 at 9:30 a.m. ET, the Citi 2026 Biopharma Back to School Summit on September 10 at 2:20 p.m. ET, and the H.C. Wainwright 28th Annual Global Investment Conference on September 15 at 9:00 a.m. ET. Live webcasts and 60-day replays will be available in the Investors section of the Maze website.
Details
News Market Reaction – MAZE
On Sep 2, the day this news came out, MAZE closed 0.72% above the previous close. Relative volume reached 1.7x the daily average during tracking.
Data tracked by StockTitan Argus for the Sep 2 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that company management will participate in three upcoming investor conferences:
- Wells Fargo 21st Annual Healthcare Conference; fireside chat on Wednesday, September 9, 2026, at 9:30 a.m. ET
- Citi 2026 Biopharma Back to School Summit; fireside chat on Thursday, September 10, 2026, at 2:20 p.m. ET
- H.C. Wainwright 28th Annual Global Investment Conference; fireside chat on Tuesday, September 15, 2026, at 9:00 a.m. ET
Live webcasts of the events will be available in the Investors section of the Maze Therapeutics website at www.mazetx.com and archived for 60 days following the presentations.
About Maze Therapeutics
Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel small molecule precision medicines for patients with kidney and metabolic diseases. Guided by its Compass™ platform, Maze pursues genetically validated targets by integrating variant discovery and functionalization to discover and advance small molecule programs with first- or best-in-class potential. Maze’s pipeline is led by MZE829, a dual-mechanism APOL1 inhibitor in Phase 2 development for APOL1-mediated kidney disease (AMKD), and MZE782, a SLC6A19 inhibitor in Phase 2 development with the potential to treat both phenylketonuria (PKU) and chronic kidney disease (CKD). Maze is headquartered in South San Francisco. For more information, please visit mazetx.com, or follow Maze on LinkedIn and X.
IR/Corporate Contact:
Argot Partners
maze@argotpartners.com
Media Contact:
Amanda Lazaro, 1AB Media
amanda@1ABMedia.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When will Maze Therapeutics (MAZE) present at the Wells Fargo 21st Annual Healthcare Conference?
Maze Therapeutics will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026, at 9:30 a.m. ET. Company management is scheduled to speak as part of the conference’s investor-focused program.
What is the schedule for Maze Therapeutics (MAZE) at the Citi 2026 Biopharma Back to School Summit?
Maze Therapeutics is scheduled for a fireside chat at the Citi 2026 Biopharma Back to School Summit on Thursday, September 10, 2026, at 2:20 p.m. ET. The session features company management speaking with investors.
When does Maze Therapeutics (MAZE) appear at the H.C. Wainwright 28th Annual Global Investment Conference?
Maze Therapeutics will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026, at 9:00 a.m. ET. The discussion will feature members of company management.
How can investors access the webcasts of Maze Therapeutics (MAZE) September 2026 conference presentations?
Live webcasts of all three Maze Therapeutics fireside chats will be available in the Investors section of the company’s website at www.mazetx.com. The presentations will also be archived there for 60 days following each event.
What does Maze Therapeutics (MAZE) focus on in its clinical pipeline?
Maze Therapeutics is a clinical-stage biopharmaceutical company developing small molecule precision medicines for kidney and metabolic diseases. Its pipeline is led by MZE829, a dual-mechanism APOL1 inhibitor for APOL1-mediated kidney disease, and MZE782, a SLC6A19 inhibitor in Phase 2 for PKU and CKD.